A novel multikinase inhibitor SKLB‐YTH‐60 ameliorates inflammation and fibrosis in bleomycin‐induced lung fibrosis mouse models

A new FGFR inhibitor disrupts the TGF‐β1‐induced fibrotic process

(2019) Mi‐Hyoung Kim et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Pulmonary fibrosis requires cell-autonomous mesenchymal fibroblast growth factor (FGF) signaling

(2017) Robert D. Guzy et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Idiopathic pulmonary fibrosis

(2017) Fernando J. Martinez et al.   Nature Reviews Disease Primers

Fibroblast growth factor-1 attenuates TGF-β1-induced lung fibrosis

(2016) Chiko Shimbori et al.   JOURNAL OF PATHOLOGY

Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials

(2016) Luca Richeldi et al.   RESPIRATORY MEDICINE

Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials

(2015) Paul W. Noble et al.   EUROPEAN RESPIRATORY JOURNAL

Nintedanib: From Discovery to the Clinic

(2015) Gerald J. Roth et al.   JOURNAL OF MEDICINAL CHEMISTRY

Forced Vital Capacity in Idiopathic Pulmonary Fibrosis — FDA Review of Pirfenidone and Nintedanib

(2015) Banu A. Karimi-Shah et al.   NEW ENGLAND JOURNAL OF MEDICINE

miR-195 Inhibits EMT by Targeting FGF2 in Prostate Cancer Cells

(2015) Chunhui Liu et al.   PLoS One

Fibroblast growth factor receptors, developmental corruption and malignant disease

(2013) F. C. Kelleher et al.   CARCINOGENESIS

NP603, a novel and potent inhibitor of FGFR1 tyrosine kinase, inhibits hepatic stellate cell proliferation and ameliorates hepatic fibrosis in rats

(2011) Nan Lin et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Conditioned medium from amniotic mesenchymal tissue cells reduces progression of bleomycin-induced lung fibrosis

(2011) Anna Cargnoni et al.   CYTOTHERAPY

TGF-β regulates isoform switching of FGF receptors and epithelial-mesenchymal transition

(2011) Takuya Shirakihara et al.   EMBO JOURNAL

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

(2011) Paul W Noble et al.   LANCET

Incomplete expression of epithelial–mesenchymal transition markers in idiopathic pulmonary fibrosis

(2011) Patrizia Morbini et al.   PATHOLOGY RESEARCH AND PRACTICE

Myeloid-derived suppressor cells: A novel therapeutic target

(2009) Jennifer S. Ko et al.   Current Oncology Reports